427 related articles for article (PubMed ID: 31111320)
1. Emerging Evidence that ApoC-III Inhibitors Provide Novel Options to Reduce the Residual CVD.
Taskinen MR; Packard CJ; Borén J
Curr Atheroscler Rep; 2019 May; 21(8):27. PubMed ID: 31111320
[TBL] [Abstract][Full Text] [Related]
2. A human APOC3 missense variant and monoclonal antibody accelerate apoC-III clearance and lower triglyceride-rich lipoprotein levels.
Khetarpal SA; Zeng X; Millar JS; Vitali C; Somasundara AVH; Zanoni P; Landro JA; Barucci N; Zavadoski WJ; Sun Z; de Haard H; Toth IV; Peloso GM; Natarajan P; Cuchel M; Lund-Katz S; Phillips MC; Tall AR; Kathiresan S; DaSilva-Jardine P; Yates NA; Rader DJ
Nat Med; 2017 Sep; 23(9):1086-1094. PubMed ID: 28825717
[TBL] [Abstract][Full Text] [Related]
3. ApoC-III ASO promotes tissue LPL activity in the absence of apoE-mediated TRL clearance.
Ramms B; Patel S; Nora C; Pessentheiner AR; Chang MW; Green CR; Golden GJ; Secrest P; Krauss RM; Metallo CM; Benner C; Alexander VJ; Witztum JL; Tsimikas S; Esko JD; Gordts PLSM
J Lipid Res; 2019 Aug; 60(8):1379-1395. PubMed ID: 31092690
[TBL] [Abstract][Full Text] [Related]
4. APOC-III Antisense Oligonucleotides: A New Option for the Treatment of Hypertriglyceridemia.
Schmitz J; Gouni-Berthold I
Curr Med Chem; 2018; 25(13):1567-1576. PubMed ID: 28595549
[TBL] [Abstract][Full Text] [Related]
5. APOC-III: a Gatekeeper in Controlling Triglyceride Metabolism.
Giammanco A; Spina R; Cefalù AB; Averna M
Curr Atheroscler Rep; 2023 Mar; 25(3):67-76. PubMed ID: 36689070
[TBL] [Abstract][Full Text] [Related]
6. Apolipoprotein C-III inhibits triglyceride hydrolysis by GPIHBP1-bound LPL.
Larsson M; Allan CM; Jung RS; Heizer PJ; Beigneux AP; Young SG; Fong LG
J Lipid Res; 2017 Sep; 58(9):1893-1902. PubMed ID: 28694296
[TBL] [Abstract][Full Text] [Related]
7. Apolipoproteins C-I and C-III inhibit lipoprotein lipase activity by displacement of the enzyme from lipid droplets.
Larsson M; Vorrsjö E; Talmud P; Lookene A; Olivecrona G
J Biol Chem; 2013 Nov; 288(47):33997-34008. PubMed ID: 24121499
[TBL] [Abstract][Full Text] [Related]
8. The next generation of triglyceride-lowering drugs: will reducing apolipoprotein C-III or angiopoietin like protein 3 reduce cardiovascular disease?
Reeskamp LF; Tromp TR; Stroes ESG
Curr Opin Lipidol; 2020 Jun; 31(3):140-146. PubMed ID: 32324598
[TBL] [Abstract][Full Text] [Related]
9. Apolipoprotein C-III: a potent modulator of hypertriglyceridemia and cardiovascular disease.
Kohan AB
Curr Opin Endocrinol Diabetes Obes; 2015 Apr; 22(2):119-25. PubMed ID: 25692924
[TBL] [Abstract][Full Text] [Related]
10. Antisense oligonucleotide inhibition of apolipoprotein C-III reduces plasma triglycerides in rodents, nonhuman primates, and humans.
Graham MJ; Lee RG; Bell TA; Fu W; Mullick AE; Alexander VJ; Singleton W; Viney N; Geary R; Su J; Baker BF; Burkey J; Crooke ST; Crooke RM
Circ Res; 2013 May; 112(11):1479-90. PubMed ID: 23542898
[TBL] [Abstract][Full Text] [Related]
11. The Roles of ApoC-III on the Metabolism of Triglyceride-Rich Lipoproteins in Humans.
Borén J; Packard CJ; Taskinen MR
Front Endocrinol (Lausanne); 2020; 11():474. PubMed ID: 32849270
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of Angiopoietin-Like Protein 3 or 3/8 Complex and ApoC-III in Severe Hypertriglyceridemia.
Larouche M; Khoury E; Brisson D; Gaudet D
Curr Atheroscler Rep; 2023 Dec; 25(12):1101-1111. PubMed ID: 38095804
[TBL] [Abstract][Full Text] [Related]
13. Apolipoprotein C-II: the re-emergence of a forgotten factor.
Wolska A; Reimund M; Remaley AT
Curr Opin Lipidol; 2020 Jun; 31(3):147-153. PubMed ID: 32332429
[TBL] [Abstract][Full Text] [Related]
14. Metabolic characterisation of disturbances in the APOC3/triglyceride-rich lipoprotein pathway through sample-based recall by genotype.
Corbin LJ; Hughes DA; Chetwynd AJ; Taylor AE; Southam AD; Jankevics A; Weber RJM; Groom A; Dunn WB; Timpson NJ
Metabolomics; 2020 Jun; 16(6):69. PubMed ID: 32494907
[TBL] [Abstract][Full Text] [Related]
15. ANGPTL3 and ApoC-III inhibitors for treating hypertriglyceridemia in context: horses for courses?
Chan DC; Watts GF
Curr Opin Lipidol; 2024 Jun; 35(3):101-109. PubMed ID: 38372218
[TBL] [Abstract][Full Text] [Related]
16. Apolipoprotein C-III: understanding an emerging cardiovascular risk factor.
Ooi EM; Barrett PH; Chan DC; Watts GF
Clin Sci (Lond); 2008 May; 114(10):611-24. PubMed ID: 18399797
[TBL] [Abstract][Full Text] [Related]
17. Apolipoprotein C-II: New findings related to genetics, biochemistry, and role in triglyceride metabolism.
Wolska A; Dunbar RL; Freeman LA; Ueda M; Amar MJ; Sviridov DO; Remaley AT
Atherosclerosis; 2017 Dec; 267():49-60. PubMed ID: 29100061
[TBL] [Abstract][Full Text] [Related]
18. Apolipoprotein C-III: From Pathophysiology to Pharmacology.
Norata GD; Tsimikas S; Pirillo A; Catapano AL
Trends Pharmacol Sci; 2015 Oct; 36(10):675-687. PubMed ID: 26435212
[TBL] [Abstract][Full Text] [Related]
19. A dual apolipoprotein C-II mimetic-apolipoprotein C-III antagonist peptide lowers plasma triglycerides.
Wolska A; Lo L; Sviridov DO; Pourmousa M; Pryor M; Ghosh SS; Kakkar R; Davidson M; Wilson S; Pastor RW; Goldberg IJ; Basu D; Drake SK; Cougnoux A; Wu MJ; Neher SB; Freeman LA; Tang J; Amar M; Devalaraja M; Remaley AT
Sci Transl Med; 2020 Jan; 12(528):. PubMed ID: 31996466
[TBL] [Abstract][Full Text] [Related]
20. ApoCIII as a Cardiovascular Risk Factor and Modulation by the Novel Lipid-Lowering Agent Volanesorsen.
Rocha NA; East C; Zhang J; McCullough PA
Curr Atheroscler Rep; 2017 Nov; 19(12):62. PubMed ID: 29124482
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
